Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "Global Thalassemia Market (2023-2028) by Type, Disease Type, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive overview and detailed insights into the global thalassemia market.
It covers data and analysis related to thalassemia prevalence, treatment methods, market size, growth drivers, challenges, and market trends across eleven key countries: The United States, Canada, China, India, Japan, South Korea, Germany, France, the Netherlands, Norway, and the United Kingdom.
The report sources data from proprietary databases, primary and secondary research, and in-house analysis conducted by the publisher's team of industry experts.
Scope:
The report encompasses the following:
- A detailed analysis of the global thalassemia market and an in-depth exploration of the key countries
- Identification of key growth drivers and challenges on a global scale
- Market size evaluation in terms of both volume and value, covering global and country-specific perspectives
- Analysis of policies related to electric vehicles and charging infrastructure in each key country
- Segmentation of the electric vehicle market globally and within each key country
- Overview of major participants in the global thalassemia market and their market shares in key countries
Reasons to Buy:
- This report facilitates informed decision-making by providing trend analysis within the electric vehicles market.
- It aids in the development of effective business strategies by understanding the market's drivers and challenges.
- Companies can position themselves advantageously to capitalize on growth opportunities within the industry.
- This report helps maximize potential growth in the electric vehicles market. Identification of key partners, strategic geographies, and avenues for business development.
- Assistance in responding to market dynamics, shaping strategies, and assessing prospects.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 202 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $3.61 Billion |
| Forecasted Market Value (USD) by 2028 | $4.88 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
Market Dynamics
Drivers
- Rising Prevalence of Thalassemia
- Advancements in Diagnosis and Treatment in Innovation
Restraints
- High Cost of the Thalassemia Treatment
Opportunities
- Increasing Incidence of Beta-Thalassemia
- Current Trends in the Management of Beta Thalassemia
Challenges
- Lack of Voluntary Nonremunerated Blood Donors
Companies Mentioned
- Acceleron Pharma, Inc.
- Alnylam Pharmaceuticals, Inc.
- ApoPharma, Inc.
- Bellicum Pharmaceuticals
- Bluebird Bio Corp.
- Calimmune, Inc.
- CRISPR Therapeutics
- Editas Medicine, Inc.
- Errant Gene Therapeutics LLC
- Fresenius Kabi Ag
- Gamida Cell Ltd
- GlaxoSmithKline PLC
- Incyte Corp.
- Ionis Pharmaceuticals, Inc.
- Novartis Ag
- Sangamo Therapeutics, Inc.
- SG Pharma Pvt. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vifor Pharma
Market Segmentation
The Global Thalassemia Market is segmented based on Type, Disease Type, End User, and Geography.
- By Type, the market is classified into Iron Chelating Drugs, Blood Transfusions, Folic Acid Supplements, Gene Therapy, and Others.
The iron chelation Drugs segment grew the most due to rising thalassemia drug demand and public awareness. It is anticipated to maintain its dominance during the market forecast period. The demand for thalassemia drugs has also increased due to the rising prevalence of thalassemia cases, which is helping the market to grow.
- By Disease Type, the market is classified into Alpha and Beta.
The alpha thalassemia segment dominated the market. This is due to increased thalassemia gene therapy demand across North America. Additionally, due to increased R&D activities for alpha thalassemia, the segment for alpha thalassemia is predicted to grow throughout the forecast period.
- By End User, the market is classified into Hospitals, Research Institutes, and Others. Collaboration among hospitals, research institutes, and other stakeholders is crucial for enhancing thalassemia care, advancing medical knowledge, and improving the lives of individuals affected by this genetic disorder.
- By Geography, the market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
The alpha thalassemia category dominated the market. An increase in thalassemia gene therapy demand across the Americas explains this. Additionally, due to increased R&D activities for alpha thalassemia, the segment for alpha thalassemia is predicted to grow at a CAGR throughout the forecast period.
For more information about this report visit https://www.researchandmarkets.com/r/eheaud
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
